METHOD FOR PREDICTING CYTOPROTECTIVE EFFECT OF IMMUNOGLOBULINS FOR INTRAVENOUS ADMINISTRATION IN THERAPY OF FEMALES WITH RECURRENT PREGNANCY LOSS AND DIAGNOSED ANTI-PHOSPHOLIPID SYNDROME Russian patent published in 2015 - IPC G01N33/48 

FIELD: medicine.

SUBSTANCE: portion of endothelial cell culture is pre-processed with immunoglobulins for intravenous administration, while the other portion is left unprocessed, cultured with female's blood serum to measure a percentage of non-viable endothelial cells processed with immunoglobulins for intravenous administration. A percentage of non-viable endothelial cells unprocessed with immunoglobulins for intravenous administration is also determined. The cytoprotective effect is calculated in per cent by formula: CE=100-100X/X1, wherein X is the percentage of non-viable endothelial cells processed with immunoglobulins after culturing with blood serum; X1 is the percentage of non-viable endothelial cells unprocessed with immunoglobulins after culturing with blood serum. If the derived value is more than 55%, the cytoprotective effect is considered to be positive.

EFFECT: method enables predicting the cytoprotective effect of intravenous immunoglobulins both in treating the females suffering recurrent pregnancy loss and diagnosed anti-phospholipid syndrome, and in treating some other diseases related to endothelial injuries and derived endothelial dysfunction.

6 dwg, 3 tbl, 2 ex